SCHEMBL3012771

SCHEMBL3012771

COc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)c(Cl)c4)cs3)CC2)c(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 4/20 0.38
EPHA2 P29317 4/20 0.38
LMNA P02545 3/20 0.37
MAPT P10636 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
KDR P35968 3/20 0.37
EPHB4 P54760 3/20 0.37
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP19A1 P11511 1/20 0.34
F2RL3 Q96RI0 3/20 0.34
GPR6 P46095 1/20 0.34
CCR2 P41597 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012724 0.93 ALDH1A1 (0.41) ERBB2EPHA2MAPTKDREPHB4
SCHEMBL3009166 0.93 MAPT (0.39) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3012968 0.93 MAPT (0.39) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3014404 0.92 MAPT (0.39) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3018545 0.91 ALDH1A1 (0.41) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3014972 0.91 MAPT (0.38) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3016729 0.91 ALDH1A1 (0.41) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3002013 0.89 MAPT (0.37) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3006114 0.89 MAPT (0.40) LMNAMAPTTDP1ALDH1A1HPGD
SCHEMBL3014322 0.89 MAPT (0.38) LMNAMAPTTDP1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ERBB2 3807/4885EPHA2 4810/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.